Table 1.
Patient demographics and clinical characteristics.
Table 2.
Baseline disease assessments by examining RECIST targets versus ALL metastases.
Figure 1.
The proportions of categories of response a) by patients (N = 24), b) by metastases (N = 135).
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
Figure 2.
Inter-patient heterogeneneity of response and progression with CombiDT.
Plot of the percent change in the sum of diameters of all metastases ≥5 mm within an individual patient compared to baseline at various time points during treatment with CombiDT until disease progression. Each line represents an individual patient. Abbreviations: E, disease progressing due to existing lesions; N, new lesions; N+E, new and existing lesions; O→, ongoing response without progression; T, treatment ceased due to toxicity.
Figure 3.
The degree of overall best response for each patient by RECIST and ALL metastasis disease assessments.
Figure 4.
The best response of each individual metastasis within each patient.
Abbrevations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
Figure 5.
Correlation of the response of individual metastases at first scan versus best response (N = 135).
Table 3.
Factors influencing individual metastasis response to treament; time to best response by metastasis site, and the effect of metastasis site and size on response.
Figure 6.
Intra-patient heterogeneneity of response and progression with CombiDT.
Example plots of the percent change in the diameter of individual metastases within four patients (a-d) compared to baseline at various time points during treatment until overall disease progression. The degree and kinetics of response of individual metastases vary within a patient. Similarly, progression often occurs only in a subset of the overall tumour burden. Patient D had disease progression in new lesions only.
Figure 7.
Intra-patient heterogeneity of disease progression.
The number and type of metastases progressing at time of disease progression.
Table 4.
Univariate progression-free and overall survival.